Hagström, Hannes

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 2,287

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,069

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,067

Changing epidemiology, global trends and implications for outcomes of NAFLD

Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 765

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Gut

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 673

99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical

Hagström, H., Vessby, J., Ekstedt, M., & Shang, Y. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 372

Natural history and progression of metabolic dysfunction-associated steatotic liver disease

Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 310

Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease

Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 250

Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet—a randomised controlled trial

Holmer, M., Lindqvist, C., Petersson, S., Moshtaghi-Svensson, J., Tillander, V., Brismar, T. B., Hagström, H., & Stål, P. (2021) · JHEP Reports

Liver Disease Diagnosis and TreatmentDietary Effects on Health

Cited by 224

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events

Boursier, J., Hagström, H., Ekstedt, M., Moreau, C., Bonacci, M., Cure, S., Ampuero, J., Nasr, P., Tallab, L., Canivet, C. M., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 206

Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease

Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 199

Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease

Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 182

Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study

Simon, T. G., Roelstraete, B., Sharma, R., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Cited by 176

Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease

Hagström, H., Nasr, P., Ekstedt, M., Stål, P., Hultcrantz, R., & Kechagias, S. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 132

Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study

Shang, Y., Widman, L., & Hagström, H. (2022) · Neurology

Dementia and Cognitive Impairment ResearchLiver Disease Diagnosis and Treatment

Cited by 85

Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease

Stiglund, N., Strand, K., Cornillet, M., Stål, P., Thorell, A., Zimmer, C. L., Näslund, E., Karlgren, S., Nilsson, H., Mellgren, G., et al. (2019) · Frontiers in Immunology

Immune Cell Function and InteractionLiver Disease Diagnosis and Treatment

Cited by 72

Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study

Ebrahimi, F., Hagström, H., Sun, J., Bergman, D., Shang, Y., Yang, W., Roelstraete, B., & Ludvigsson, J. F. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Cited by 65

Implementation of a liver health check in people with type 2 diabetes

Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 63

Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes

Shang, Y., Grip, E. T., Modica, A., Skröder, H., Ström, O., Ntanios, F., Gudbjörnsdottir, S., & Hagström, H. (2024) · Diabetes Care

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 61

Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease

Hagström, H., Kechagias, S., & Ekstedt, M. (2022) · Journal of Internal Medicine

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 52